Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)
Recruiting
Phase 4
Interventional Study
Femoral Neck Fractures
Femur Head Necrosis
Hip Fractures
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 60
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to study the analgesic effect of liposomal bupivacaine plus bupivacaine for Pericapsular Nerve Group (PENG) block in postoperative pain management following hip replacement surgery. It will also assess the safety of liposomal bupivacaine for this purpose. The main questions it aims to answer are:
1. Is liposomal bupivacaine plus bupivacaine superior to ropivacai…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* American Society of Anesthesiologists(ASA) I\~II
* Normal coagulation
* Clinical diagnosis of hip fracture
Exclusion Criteria:
* Presence of severe systemic diseases or ASA grade III or higher
* Allergy to amide local anesthetics
Contacts